CORD-19:500c5ea0961b573ba5355d364ca94c00a0a26e4a / 15032-15212 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T104","span":{"begin":0,"end":180},"obj":"Sentence"},{"id":"TextSentencer_T104","span":{"begin":0,"end":180},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Given that FKBP52 is a co-chaperone of HSP90 [17,23], we wanted to discard if 171 the observed inhibitory effect on NS1 secretion might be related to a reduction in HSP90 activity."}

{"project":"CORD-PICO","denotations":[{"id":"p1_all42","span":{"begin":11,"end":17},"obj":"Intervention"},{"id":"p2_i12","span":{"begin":11,"end":17},"obj":"Pharmacological"}],"text":"Given that FKBP52 is a co-chaperone of HSP90 [17,23], we wanted to discard if 171 the observed inhibitory effect on NS1 secretion might be related to a reduction in HSP90 activity."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T91","span":{"begin":116,"end":119},"obj":"Disease"},{"id":"T73071","span":{"begin":116,"end":119},"obj":"Disease"}],"attributes":[{"id":"A91","pred":"mondo_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/MONDO_0008104"},{"id":"A59519","pred":"mondo_id","subj":"T73071","obj":"http://purl.obolibrary.org/obo/MONDO_0008104"}],"text":"Given that FKBP52 is a co-chaperone of HSP90 [17,23], we wanted to discard if 171 the observed inhibitory effect on NS1 secretion might be related to a reduction in HSP90 activity."}